<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ScientificWorldJournal</journal-id><journal-id journal-id-type="iso-abbrev">ScientificWorldJournal</journal-id><journal-id journal-id-type="publisher-id">TSWJ</journal-id><journal-title-group><journal-title>The Scientific World Journal</journal-title></journal-title-group><issn pub-type="ppub">2356-6140</issn><issn pub-type="epub">1537-744X</issn><publisher><publisher-name>TheScientificWorldJOURNAL</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17619791</article-id><article-id pub-id-type="pmc">5901055</article-id><article-id pub-id-type="publisher-id">850823</article-id><article-id pub-id-type="doi">10.1100/tsw.2007.134</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Is There Any Point in a Corticosteroid Treatment of Intermittent Asthma?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stankovi&#x00107;</surname><given-names>Ivana</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pej&#x0010d;i&#x00107;</surname><given-names>Tatjana</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Milenkovi&#x00107;</surname><given-names>Branislava</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jovanovi&#x00107;</surname><given-names>Dragana</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ran&#x0010d;i&#x00107;</surname><given-names>Milan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>
The Clinic for Lung Diseases and TBC,
University Hospital,
Ni&#x00161;,
Serbia
</aff><aff id="I2">
<sup>2</sup>
The Institute for Lung Diseases,
University Hospital,
Belgrade,
Serbia
</aff><author-notes><corresp id="cor1">*Ivana Stankovi&#x00107;: <email>ivanas@bankerinter.net</email></corresp><fn fn-type="other"><p>Academic Editor: Joav Merrick</p></fn></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>3</day><month>7</month><year>2007</year></pub-date><volume>7</volume><fpage>1082</fpage><lpage>1089</lpage><history><date date-type="received"><day>11</day><month>2</month><year>2007</year></date><date date-type="rev-recd"><day>8</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Ivana Stankovic et al.</copyright-statement><copyright-year>2007</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>International guidelines advocate the early introduction of inhaled corticosteroids (ICS) in all types of persistent asthma. Our study was undertaken to assess the effects of ICS on bronchial hyperresponsiveness (BHR) as a hallmark of inflammation, and to assess the symptoms, the use of rescue medications, and the parameters of lung function in patients with mild intermittent asthma. The patients with intermittent asthma (n = 85) were randomly allocated to a treatment with ICS, beclomethasone dipropionate 250 &#x003bc;g/day and short-acting &#x003b2;2 agonists salbutamol as needed (Group A, n = 45) or to a treatment with only short-acting &#x003b2;2 agonists as needed (Group B, n = 40) during the 6-month treatment period. At the end of the study, in Group A, we found a statistically significant decrease of BHR (PD<sub>20</sub> 0.98 vs. 2.07) (p &#x0003c; 0.001), diurnal peak expiratory flow (PEF) variability (17.9 vs. 13.8) (p &#x0003c; 0.001), symptom scores (0.63 vs. 0.30) (p &#x0003c; 0.001), and used rescue medication (p &#x0003c; 0.001), while the parameters of lung function remained unchanged except for forced expiratory volume in 1 sec (FEV1), which had a statistically significant increase (3.58 vs. 3.66) (p &#x0003c; 0.001). In Group B, there was a statistically significant decrease of lung function parameters FEV1 (3.80 vs. 3.71) (p &#x0003c; 0.001), forced vital capacity (FVC) (4.43 vs. 4.37) (p &#x0003c; 0.001), FEV1/FVC (88.2 vs. 85.3) (p &#x0003c; 0.05), PEF (8.05 vs. 7.51) (p &#x0003c; 0.01), PEF variability (17.85 vs. 18.33) (p &#x0003c; 0.001), increased BHR (PD<sub>20</sub> 1.04 vs. 0.62) (p &#x0003c; 0.05), and symptom scores (0.46 vs. 0.62) (p &#x0003c; 0.01), as well as the use of rescue medication during the day (p &#x0003c; 0.001). Early introduction of low doses of ICS may be more beneficial than &#x003b2;2 agonists alone in patients with intermittent asthma.</p></abstract><kwd-group><kwd>intermittent asthma</kwd><kwd>bronchial hyperresponsiveness</kwd><kwd>inhaled corticosteroid</kwd></kwd-group></article-meta></front></article>